166 related articles for article (PubMed ID: 37207301)
1. Genetic and Genomic Testing for Prostate Cancer: Beyond DNA Repair.
Herberts C; Wyatt AW; Nguyen PL; Cheng HH
Am Soc Clin Oncol Educ Book; 2023 May; 43():e390384. PubMed ID: 37207301
[TBL] [Abstract][Full Text] [Related]
2. Germline Testing in Prostate Cancer: When and Who to Test.
Sokolova A; Cheng H
Oncology (Williston Park); 2021 Oct; 35(10):645-653. PubMed ID: 34669358
[TBL] [Abstract][Full Text] [Related]
3. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
Athie A; Arce-Gallego S; Gonzalez M; Morales-Barrera R; Suarez C; Casals Galobart T; Hernandez Viedma G; Carles J; Mateo J
Curr Oncol Rep; 2019 Mar; 21(5):42. PubMed ID: 30919167
[TBL] [Abstract][Full Text] [Related]
4. Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
Merseburger AS; Waldron N; Ribal MJ; Heidenreich A; Perner S; Fizazi K; Sternberg CN; Mateo J; Wirth MP; Castro E; Olmos D; Petrylak DP; Chowdhury S
Eur Urol; 2021 Apr; 79(4):519-529. PubMed ID: 33494937
[TBL] [Abstract][Full Text] [Related]
5. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
6. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
[TBL] [Abstract][Full Text] [Related]
7. Molecular Genetics of Prostate Cancer and Role of Genomic Testing.
Akhoundova D; Feng FY; Pritchard CC; Rubin MA
Surg Pathol Clin; 2022 Dec; 15(4):617-628. PubMed ID: 36344179
[TBL] [Abstract][Full Text] [Related]
8. Bringing Prostate Cancer Germline Genetics into Clinical Practice.
Das S; Salami SS; Spratt DE; Kaffenberger SD; Jacobs MF; Morgan TM
J Urol; 2019 Aug; 202(2):223-230. PubMed ID: 30730411
[TBL] [Abstract][Full Text] [Related]
9. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
Dhawan M; Ryan CJ; Ashworth A
Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
[TBL] [Abstract][Full Text] [Related]
10. Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.
Hofstad M; Huang EY; Woods A; Yin Y; Desai NB; Raj GV
Crit Rev Oncog; 2022; 27(1):81-96. PubMed ID: 35993980
[TBL] [Abstract][Full Text] [Related]
11. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
Dariane C; Timsit MO
Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitors in advanced prostate cancer: when to use them?
Díaz-Mejía N; García-Illescas D; Morales-Barrera R; Suarez C; Planas J; Maldonado X; Carles J; Mateo J
Endocr Relat Cancer; 2021 Jul; 28(8):T79-T93. PubMed ID: 34256353
[TBL] [Abstract][Full Text] [Related]
13. PARP Inhibition in Advanced Prostate Cancer.
Fenton SE; Chalmers ZR; Hussain M
Cancer J; 2021 Nov-Dec 01; 27(6):457-464. PubMed ID: 34904808
[TBL] [Abstract][Full Text] [Related]
14. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Antonarakis ES; Gomella LG; Petrylak DP
Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
[TBL] [Abstract][Full Text] [Related]
15. BRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations.
Shah S; Rachmat R; Enyioma S; Ghose A; Revythis A; Boussios S
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884434
[TBL] [Abstract][Full Text] [Related]
16. Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
Castro E; Mateo J; Olmos D; de Bono JS
Cancer J; 2016; 22(5):353-356. PubMed ID: 27749330
[TBL] [Abstract][Full Text] [Related]
17. BRCAness and prostate cancer: diagnostic and therapeutic considerations.
Dhawan M; Ryan CJ
Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):488-498. PubMed ID: 30131605
[TBL] [Abstract][Full Text] [Related]
18. Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer.
Deniz M; Zengerling F; Gundelach T; Moreno-Villanueva M; Bürkle A; Janni W; Bolenz C; Kostezka S; Marienfeld R; Benckendorff J; Friedl TWP; Wiesmüller L; Rall-Scharpf M
Mech Ageing Dev; 2021 Jun; 196():111494. PubMed ID: 33887280
[TBL] [Abstract][Full Text] [Related]
19. Impact of Pathogenic Germline DNA Damage Repair alterations on Response to Intense Neoadjuvant Androgen Deprivation Therapy in High-risk Localized Prostate Cancer.
Berchuck JE; Zhang Z; Silver R; Kwak L; Xie W; Lee GM; Freedman ML; Kibel AS; Van Allen EM; McKay RR; Taplin ME
Eur Urol; 2021 Sep; 80(3):295-303. PubMed ID: 33888356
[TBL] [Abstract][Full Text] [Related]
20. DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review.
Armstrong N; Quek RG; Ryder S; Ross J; Buksnys T; Forbes C; Fox KM; Castro E
Future Oncol; 2021 Mar; 17(7):853-864. PubMed ID: 33263430
[No Abstract] [Full Text] [Related]
[Next] [New Search]